Suppression of BRD4 using small compounds such as JQ1, I-BET151 and MS417 has been shown profound efficacy against a wide range of cancers such as diffuse large B cell lymphoma, AML, MLL, non-small cell lung cancer, breast cancer, pancreatic cancer and melanoma [10,15,16,19,23,25]. Here, KMT2A is linked to acute myeloid leukemia.